title: Chemotherapy for anaplastic thyroid cancer using docetaxel and cisplatin: report of eight cases.
abstract: Anaplastic thyroid carcinoma has a dismal prognosis and lacks an established therapeutic strategy. We have recently conducted chemotherapy with docetaxel and cisplatin as part of multimodal treatment for eight patients with anaplastic thyroid carcinoma. Docetaxel (75 mg/m²) and cisplatin (75 mg/m²) were administered on day 1 every 4 weeks for six courses. This chemotherapy was used as induction therapy in one patient, as therapy for distant metastases in five patients and as postoperative adjuvant therapy in two patients. Three patients showed partial responses and three patients showed stable disease. After excluding the two patients receiving the treatment as adjuvant therapy the response rate was 50 %. Grade 3 or 4 leukocytopenia occurred in seven patients (88 %), but these adverse events were tolerable. Chemotherapy with docetaxel and cisplatin may thus be feasible for anaplastic thyroid carcinoma.
authors.affiliation: Division of Head and Neck, Cancer Institute Hospital, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan, akira.seto@jfcr.or.jp.
authors.forename: Akira
authors.initials: A
authors.lastname: Seto
authors.forename: Iwao
authors.initials: I
authors.lastname: Sugitani
authors.forename: Kazuhisa
authors.initials: K
authors.lastname: Toda
authors.forename: Kazuyoshi
authors.initials: K
authors.lastname: Kawabata
authors.forename: Shunji
authors.initials: S
authors.lastname: Takahashi
authors.forename: Takashi
authors.initials: T
authors.lastname: Saotome